Lineage Cell Therapeutics Inc [AMEX: LCTX] traded at a low on Wednesday, posting a -28.99 loss after which it closed the day’ session at $0.64.
The results of the trading session contributed to over 9899909 shares changing hands. Over the past one week, the price volatility of Lineage Cell Therapeutics Inc stands at 11.20% while the volatility over the past one month is 6.52%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for LCTX stock reached $121.12 million, with 188.84 million shares outstanding and 188.00 million shares in the current float. Compared to the average trading volume of 417.28K shares, LCTX reached a trading volume of 9899909 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Lineage Cell Therapeutics Inc [LCTX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for LCTX shares is $4.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on LCTX stock is a recommendation set at 1.43. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Craig Hallum have made an estimate for Lineage Cell Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 20, 2024. While these analysts kept the previous recommendation, Robert W. Baird raised their target price to Outperform. The new note on the price target was released on November 02, 2022, representing the official price target for Lineage Cell Therapeutics Inc stock. Previously, the target price had yet another raise to $4, while B. Riley Securities analysts kept a Buy rating on LCTX stock.
The Average True Range (ATR) for Lineage Cell Therapeutics Inc is set at 0.07, with the Price to Sales ratio for LCTX stock in the period of the last 12 months amounting to 13.89. The Price to Book ratio for the last quarter was 1.83, with the Price to Cash per share for the same quarter was set at 0.17.
How has LCTX stock performed recently?
Lineage Cell Therapeutics Inc [LCTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -29.75. With this latest performance, LCTX shares dropped by -27.58% in over the last four-week period, additionally sinking by -38.91% over the last 6 months – not to mention a drop of -40.06% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for LCTX stock in for the last two-week period is set at 28.64, with the RSI for the last a single of trading hit 22.40, and the three-weeks RSI is set at 33.12 for Lineage Cell Therapeutics Inc [LCTX]. The present Moving Average for the last 50 days of trading for this stock 0.8807, while it was recorded at 0.8347 for the last single week of trading, and 1.0150 for the last 200 days.
Lineage Cell Therapeutics Inc [LCTX]: Deeper insight into the fundamentals
Lineage Cell Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.48 and a Current Ratio set at 2.48.
Insider trade positions for Lineage Cell Therapeutics Inc [LCTX]
There are presently around $50.56%, or 50.79%% of LCTX stock, in the hands of institutional investors. The top three institutional holders of LCTX stocks are: BROADWOOD CAPITAL INC with ownership of 41.67 million shares, which is approximately 22.7798%. BLACKROCK INC., holding 9.56 million shares of the stock with an approximate value of $$9.53 million in LCTX stocks shares; and BLACKROCK INC., currently with $$8.45 million in LCTX stock with ownership which is approximately 4.6329%.
